Literature DB >> 9591630

Cytogenetic analysis of 46 pleomorphic soft tissue sarcomas and correlation with morphologic and clinical features: a report of the CHAMP Study Group. Chromosomes and MorPhology.

F Mertens1, C D Fletcher, P Dal Cin, I De Wever, N Mandahl, F Mitelman, J Rosai, A Rydholm, R Sciot, G Tallini, H Van den Berghe, R Vanni, H Willén.   

Abstract

With the aim of identifying objective cytogenetic-morphologic correlations, we evaluated 46 pleomorphic soft tissue sarcomas (mainly diagnosed originally as malignant fibrous histiocytomas) with clonal chromosome aberrations both cytogenetically and morphologically as part of an international collaborative study. By detailed histopathologic examination, most cases could be categorized into specific tumor types. Eight sarcomas were diagnosed as lipogenic (4 pleomorphic, 1 combined pleomorphic and myxoid/round cell, and 3 dedifferentiated liposarcomas), 19 as myogenic [11 leiomyosarcomas, 1 rhabdomyosarcoma, 4 myosarcomas not otherwise specified (NOS), and 3 probable myosarcomas NOS], 8 as myxofibrosarcomas, 1 as a malignant peripheral nerve sheath tumor, 1 as malignant mesenchymoma, 1 as extraskeletal osteosarcoma, I as sarcoma resembling proliferative fasciitis, and 7 as pleomorphic sarcomas NOS. In a three-grade system, 10 tumors were grade 2 and 36 were grade 3. The majority had highly complex karyotypes. A total of 24 recurrent abnormalities (defined by their presence in at least five cases) were detected: ring chromosomes, homogeneously staining regions (hsr) and/or double minute chromosomes (dmin), and structural rearrangement of 22 different chromosome bands or regions. The frequency and distribution of the recurrent karyotypic features were uneven. Grade 3 tumors displayed, on average, more aberrations per case than did grade 2 tumors. Nine of the selected abnormalities, including hsr/dmin and rearrangements of 19p13 and 19q13, were found only among the high-grade tumors. When the tumors were subdivided according to lineage of differentiation, the highest frequency of aberrations was seen in pleomorphic sarcomas NOS, followed by myxofibrosarcomas, myogenic sarcomas, and lipogenic sarcomas. None of the selected rearrangements was, however, specific for any of these subgroups. The sole consistent cytogenetic-morphologic association was that all three dedifferentiated liposarcomas had multiple abnormal clones, at least one of which contained supernumerary ring chromosomes. Due mainly to karyotype complexity, it therefore seems unlikely that cytogenetic analysis can assist in the differential diagnostic subclassification of pleomorphic sarcomas, nor was there any clear-cut indication that the karyotypic picture could be used to predict clinical outcome. Although the mean number of recurrent chromosome aberrations was almost twice as high in sarcomas that gave rise to metastases as among those that did not, no particular aberration was restricted to either of the two subgroups.

Entities:  

Mesh:

Year:  1998        PMID: 9591630     DOI: 10.1002/(sici)1098-2264(199805)22:1<16::aid-gcc3>3.0.co;2-a

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  27 in total

1.  Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.

Authors:  Myriam Goldstein; Isaac Meller; Josephine Issakov; Avi Orr-Urtreger
Journal:  Neoplasia       Date:  2006-05       Impact factor: 5.715

2.  Myxoinflammatory fibroblastic sarcoma: a clinicopathologic analysis of 104 cases, with emphasis on predictors of outcome.

Authors:  William B Laskin; John F Fetsch; Markku Miettinen
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

3.  Molecular basis of differentiation therapy for soft tissue sarcomas.

Authors:  Gaurav Luther; Richard Rames; Eric R Wagner; Gaohui Zhu; Qing Luo; Yang Bi; Stephanie H Kim; Jian-Li Gao; Enyi Huang; Ke Yang; Linyuan Wang; Xing Liu; Mi Li; Ning Hu; Yuxi Su; Xiaoji Luo; Liang Chen; Jinyong Luo; Rex C Haydon; Hue H Luu; Lan Zhou; Tong-Chuan He
Journal:  Trends Cancer Res       Date:  2010

4.  Activation of the Akt-mTOR and MAPK pathways in dedifferentiated liposarcomas.

Authors:  Takeaki Ishii; Kenichi Kohashi; Kunio Iura; Akira Maekawa; Hirofumi Bekki; Yuichi Yamada; Hidetaka Yamamoto; Kazuki Nabeshima; Hiroyuki Kawashima; Yukihide Iwamoto; Yoshinao Oda
Journal:  Tumour Biol       Date:  2015-10-30

5.  Proposal for Modification of Cahan's Criteria Utilizing Molecular Genetic Analyses for Cases without Baseline Histopathology: A Unique Method Applicable to Primary Radiosurgery.

Authors:  Aaron E Rusheen; James B Smadbeck; Lisa A Schimmenti; Eric W Klee; Michael J Link; George Vasmatzis; Matthew L Carlson
Journal:  J Neurol Surg B Skull Base       Date:  2018-05-31

Review 6.  Soft tissue sarcomas with complex genomic profiles.

Authors:  Louis Guillou; Alain Aurias
Journal:  Virchows Arch       Date:  2010-02       Impact factor: 4.064

Review 7.  Genomic characteristics of soft tissue sarcomas.

Authors:  Fredrik Mertens; Ioannis Panagopoulos; Nils Mandahl
Journal:  Virchows Arch       Date:  2009-02-03       Impact factor: 4.064

8.  Telomere lengths of translocation-associated and nontranslocation-associated sarcomas differ dramatically.

Authors:  Elizabeth Montgomery; Pedram Argani; Jessica L Hicks; Angelo M DeMarzo; Alan K Meeker
Journal:  Am J Pathol       Date:  2004-05       Impact factor: 4.307

9.  Plasma levels of miRNA-155 as a powerful diagnostic marker for dedifferentiated liposarcoma.

Authors:  Aleksandar Boro; David Bauer; Walter Born; Bruno Fuchs
Journal:  Am J Cancer Res       Date:  2016-01-15       Impact factor: 6.166

10.  Classification and subtype prediction of adult soft tissue sarcoma by functional genomics.

Authors:  Neil H Segal; Paul Pavlidis; Cristina R Antonescu; Robert G Maki; William S Noble; Diann DeSantis; James M Woodruff; Jonathan J Lewis; Murray F Brennan; Alan N Houghton; Carlos Cordon-Cardo
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.